Translational Grants Program
Translational research takes discoveries made by investigators doing basic scientific research and turns them into real-world applications to manage health. Bridging the gap between the laboratory and daily life, translational researchers are focused on converting knowledge derived from basic science into treatments, best practices or cures that benefit patients.
The National Psoriasis Foundation Translational Grants program exists to bring more and better treatments and a cure faster to people with psoriasis and psoriatic arthritis. Through these grants, the Foundation funds new and innovative research that shows a high likelihood for "translating" basic biomedical findings into improved methods of managing psoriasis and psoriatic arthritis.
The 2014 Translational Grant recipients
- Kevin Cooper, M.D., of Case Western Reserve University in Cleveland received the Dr. Alan Menter Translational Grant, named in recognition of one of the world's leading psoriatic disease experts. Cooper will determine whether systemic psoriasis treatments can reduce the risk for cardiovascular disease.
- Lorena Riol Blanco, Ph.D., of Harvard Medical School will study how pain fibers drive the production of interleukin-23 (IL-23), a protein linked to inflammation, to find new therapies for psoriasis inflammation.
- Michael Rosenblum, M.D., Ph.D., of the University of California, San Francisco, will examine the role of a special class of regulatory T-cells involved in suppressing inflammation, in people with psoriasis. He aims to discover why these cells function abnormally in psoriasis to develop treatments to repair them and treat psoriasis.